Clinical Trials Using Docetaxel

Clinical trials are research studies that involve people. The clinical trials on this list are studying Docetaxel. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 76-100 of 106

  • PTC596 in Treating Patients with Newly Diagnosed Unresectable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Chemotherapy

    This phase Ib trial studies the side effects and best dose of PTC596 in treating patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer that cannot be removed by surgery who are receiving standard of care chemotherapy. PTC596 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  • Paclitaxel, Carboplatin, and Galunisertib in Treating Patients with Newly Diagnosed, Persistent, or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Carcinosarcoma

    This phase Ib trial studies the side effects and how well paclitaxel, carboplatin, and galunisertib work in treating patients with uterine, ovarian, fallopian tube, or peritoneal carcinosarcoma that is newly diagnosed, does not go to remission despite treatment (persistent), or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Galunisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel, carboplatin, and galunisertib may work better in treating patients with uterine, ovarian, fallopian tube, or peritoneal carcinosarcoma.
    Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  • Nivolumab with or without Ipilimumab or Chemotherapy in Treating Patients with Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

    This phase II trial studies how well nivolumab works when given alone and in combination with ipilimumab or chemotherapy in treating patients with previously untreated stage I-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin, docetaxel, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab with ipilimumab or chemotherapy may work better in treating patients with non-small cell lung cancer compared to chemotherapy alone.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Androgen Deprivation Therapy, Docetaxel, External Beam Radiation Therapy, and Stereotactic Body Radiation Therapy in Treating Patients with Prostate Cancer

    This phase II trial studies how well androgen deprivation therapy, docetaxel, external beam radiation therapy, and stereotactic body radiation therapy work in treating patients with prostate cancer. Androgen deprivation therapy, such as leuprolide acetate, triptorelin, degarelix, and bicalutamide may lessen the amount of androgen made by the body. Drugs used in the chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. External beam radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving androgen deprivation therapy, docetaxel, external beam radiation therapy, and stereotactic body radiation therapy may work better in treating patients with prostate cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Bemcentinib and Docetaxel in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of bemcentinib when given together with docetaxel in treating patients with stage IV non-small cell lung cancer. Bemcentinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bemcentinib and docetaxel may work better in treating patients with non-small cell lung cancer.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor

    The aim of this study is to determine if the Investigational Medicinal Product Tedopi (OSE2101) is more effective than standard treatment in treating patients with stage IIIB NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment after failure of immune checkpoint-inhibitor regimens.
    Location: MedStar Georgetown University Hospital, Washington, District of Columbia

  • Docetaxel and Carboplatin in Treating Patients with Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1 / 2 Pathway

    This pilot phase II trial studies docetaxel and carboplatin in treating patients with castration resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic) and contains inactivated genes in the BRCA 1 / 2 pathway. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Personalized Antibodies in Treating Patients with Metastatic Stomach or Gastroesophageal Junction Cancer

    This pilot phase II trial studies personalized antibodies in treating patients with stomach or gastroesophageal junction cancer that has spread to other parts of the body. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies may block tumor growth in different ways by targeting certain cells. Testing tumor tissue for gene mutations and protein expression patterns and using drugs that target the specific profile of the tumor, may work better than standard chemotherapy in treating patients with stomach or gastroesophageal junction cancer.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Radiation Therapy with Cisplatin or Docetaxel and Cetuximab in Treating Patients with Stage III-IVB Head and Neck Cancer

    This randomized phase II trial studies how well radiation therapy in combination with cisplatin or docetaxel and cetuximab works in treating patients with stage III-IVB head and neck cancer. Radiation therapy uses high energy x rays to kill tumor cells. Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die. It may also damage blood vessels in tumor tissue. Cetuximab is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the epidermal growth factor receptor (EGFR). Cisplatin has a platinum atom at its center. The platinum may poison the cancer cells, which may cause them to die. It is not yet known whether radiation therapy is more effective when given with cisplatin or docetaxel and cetuximab in treating patients with head and neck cancer.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Metformin Hydrochloride and Combination Chemotherapy in Treating Patients with Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This partially randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy work in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help carboplatin, paclitaxel and docetaxel work better by making tumor cells more sensitive to the drugs. Studying samples of blood and tissue in the laboratory from patients receiving metformin hydrochloride may help doctors learn more about the effects of metformin hydrochloride on cells. It may also help doctors understand how well patients respond to treatment. Giving metformin hydrochloride together with combination chemotherapy may kill more tumor cells.
    Location: 12 locations

  • Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients with Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

    This phase I / II trial studies the side effects and best dose of vorinostat when given together with gemcitabine hydrochloride and docetaxel and to see how well they work in treating patients with soft tissue sarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells than giving either one alone.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

    This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
    Location: Translational Oncology Research International, Los Angeles, California

  • Docetaxel, Cisplatin and Fluorouracil in Treating Patients with Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

    This phase II trial studies how well docetaxel, cisplatin and fluorouracil work in treating patients with previously untreated stage II-IV nasal cavity and / or paranasal sinus cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

    This is a Phase 1b / 2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
    Location: 2 locations

  • TTX-030 in Combination With Immunotherapy and / or Chemotherapy in Subjects With Advanced Cancers

    This is a phase 1 / 1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and / or standard chemotherapies.
    Location: 2 locations

  • Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

    A Phase 3 Study to Compare AMG 510 with Docetaxel in Non-Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
    Location: 2 locations

  • A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

    The purpose of this study is to test the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation
    Location: 4 locations

  • A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

    The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).
    Location: See Clinical Trials.gov

  • Lenvatinib (E7080 / MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009 / E7080-G000-228 / LEAP-009)

    This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent / metastatic head and neck squamous cell carcinoma (R / M HNSCC) that have progressed after platinum therapy and a programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitor. The primary hypothesis is that pembrolizumab + lenvatinib is superior to SOC chemotherapy with respect to ORR per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review.
    Location: Medical University of South Carolina, Charleston, South Carolina

  • Docetaxel with or without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

    This phase II trial studies how well docetaxel works with or without bintrafusp alfa in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bintrafusp alfa, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving docetaxel and bintrafusp alfa in combination may work better in treating non small-cell lung cancer compared to docetaxel alone.
    Location: 3 locations

  • Gemcitabine and Docetaxel with Radiation Therapy before Surgery for the Treatment of High Grade and Greater than 5 cm Soft Tissue Sarcoma of the Extremities

    This phase I trial investigates the side effects and best dose of gemcitabine and docetaxel when given together with radiation therapy, and to see how well the combination works before surgery in treating patients with high grade soft tissue sarcoma of the upper or lower limbs (extremities) that is over 5 cm in size. Chemotherapy drugs, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving gemcitabine, docetaxel, and radiation therapy to patients with soft tissue sarcoma of the extremities may lead to a reduction in the size of the tumor prior to surgery. It may also lead to better surgical outcomes and / or reduce the risk of the tumor spreading to other parts of the body.
    Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina

  • A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

    The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.
    Location: 3 locations

  • Avelumab and Docetaxel in Treating Patients with Platinum Refractory or Ineligible Metastatic Urothelial Cancer

    This phase Ib trial studies the best dose of avelumab and how well it works when given together with docetaxel in treating patients with urothelial cancer that has spread to other places in the body and does not respond to platinum chemotherapy or cannot receive platinum chemotherapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab and docetaxel may work better in treating patients with locally advanced or metastatic urothelial cancer.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Degarelix, Bicalutamide, and Docetaxel before Surgery in Treating Patients with High Risk Metastatic Prostate Cancer

    This pilot early phase I trial studies how well degarelix, bicalutamide, and docetaxel before surgery works in treating patients with high risk prostate. Hormone therapy using degarelix and bicalutamide, may fight prostate cancer by lowering the amount of testosterone the body makes. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving degarelix, bicalutamide, and docetaxel before surgery may work better in treating patients with prostate cancer.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-risk Head and Neck Cancer

    This phase II / III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and / or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
    Location: 168 locations